Literature DB >> 17924376

Study of modification pattern-RNAi activity relationships by using siRNAs modified with 4'-thioribonucleosides.

Shuichi Hoshika1, Noriaki Minakawa, Aki Shionoya, Keiko Imada, Naoki Ogawa, Akira Matsuda.   

Abstract

A detailed study of the modification pattern-RNAi activity relationships by using siRNAs that are modified with 4'-thioribonucleosides has been carried out against photinus luciferase and renilla luciferase genes in cultured mammalian NIH/3T3, HeLa, and MIA PaCa-2 cell lines. When the photinus luciferase gene was targeted, all of the modified siRNAs showed activity equal to, or less than the unmodifed siRNA. In contrast, all modified siRNAs that have a similar modification pattern showed activity equal to or much higher than the unmodified siRNA when tested with the renilla luciferase gene. These results indicated that siRNAs such as RNA33 and RNA53, which each have four residues of the 4'-thioribonucleoside unit on both ends of the sense strand and four residues on the 3'-end of the antisense strand, were the most effective. Accordingly, we succeeded in developing modified siRNAs that have the greatest number of 4'-thioribonucleosides without loss of RNAi activity, and that exhibit potent RNAi activity against two target genes in three different cell lines. Our findings also indicate the significance of target sequences and cell lines when RNAi activity is compared with that of the unmodified siRNA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17924376     DOI: 10.1002/cbic.200700342

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  9 in total

1.  Improving gene silencing of siRNAs via tricyclo-DNA modification.

Authors:  Damian Ittig; Samuel Luisier; Jan Weiler; Daniel Schümperli; Christian J Leumann
Journal:  Artif DNA PNA XNA       Date:  2010-07

2.  Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering.

Authors:  Jesper B Bramsen; Jørgen Kjems
Journal:  Front Genet       Date:  2012-08-20       Impact factor: 4.599

3.  Thermodynamic Control of Small RNA-Mediated Gene Silencing.

Authors:  Kumiko Ui-Tei; Kenji Nishi; Tomoko Takahashi; Tatsuya Nagasawa
Journal:  Front Genet       Date:  2012-06-04       Impact factor: 4.599

4.  Intracellular stability of 2'-OMe-4'-thioribonucleoside modified siRNA leads to long-term RNAi effect.

Authors:  Mayumi Takahashi; Chisato Nagai; Hiroto Hatakeyama; Noriaki Minakawa; Hideyoshi Harashima; Akira Matsuda
Journal:  Nucleic Acids Res       Date:  2012-03-12       Impact factor: 16.971

Review 5.  Advances in siRNA therapeutics and synergistic effect on siRNA activity using emerging dual ribose modifications.

Authors:  Sumit Gangopadhyay; Kiran R Gore
Journal:  RNA Biol       Date:  2022-01       Impact factor: 4.652

Review 6.  Inhaled siRNA Formulations for Respiratory Diseases: From Basic Research to Clinical Application.

Authors:  Yulin Fan; Zhijun Yang
Journal:  Pharmaceutics       Date:  2022-06-02       Impact factor: 6.525

7.  Synthesis and characterization of 2'-modified-4'-thioRNA: a comprehensive comparison of nuclease stability.

Authors:  Mayumi Takahashi; Noriaki Minakawa; Akira Matsuda
Journal:  Nucleic Acids Res       Date:  2009-01-16       Impact factor: 16.971

8.  In vitro optimization of 2'-OMe-4'-thioribonucleoside-modified anti-microRNA oligonucleotides and its targeting delivery to mouse liver using a liposomal nanoparticle.

Authors:  Mayumi Takahashi; Naoki Yamada; Hiroto Hatakeyama; Manami Murata; Yusuke Sato; Noriaki Minakawa; Hideyoshi Harashima; Akira Matsuda
Journal:  Nucleic Acids Res       Date:  2013-09-11       Impact factor: 16.971

9.  Gene Silencing Using 4'-thioDNA as an Artificial Template to Synthesize Short Hairpin RNA Without Inducing a Detectable Innate Immune Response.

Authors:  Noriko Tarashima; Hidenori Ando; Takamitsu Kojima; Nozomi Kinjo; Yosuke Hashimoto; Kazuhiro Furukawa; Tatsuhiro Ishida; Noriaki Minakawa
Journal:  Mol Ther Nucleic Acids       Date:  2016-01-05       Impact factor: 10.183

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.